Here’s why the ResMed share price is sinking 6% today

ResMed shares are sinking after a softer than expected quarter…

| More on:
a woman looks distressed as she stares dramatically at her phone watching the Megaport share price crashing today

Image source: Getty Images.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • ResMed shares are sinking after its third quarter update disappointed
  • The company's revenue and earnings missed consensus estimates
  • Weaker revenues outside the US and margin pressures were behind the miss

The ResMed Inc (ASX: RMD) share price is ending the week deep in the red.

In late morning trade, the sleep treatment focused medical device company’s shares are down 5% to $28.87.

This is an improvement from early on when the ResMed share price was down as much as 6.5% to $28.36.

Why is the ResMed share price sinking?

Investors have been selling down the ResMed share price after the company’s third quarter update fell short of the market’s expectations.

According to the release, the company delivered a 12% increase in revenue to US$864.5 million, a 5% lift in operating income to US$234.3 million, and a 2% rise in its earnings per share up 2% to US$1.32.

Management advised that its top line growth was driven by increased demand for its sleep and respiratory care devices. Whereas its softer profit growth reflects margin pressure from higher freight, manufacturing, and employee costs.

How does this compare to expectations?

As mentioned above, the ResMed share price is falling today after its quarterly result fell short of expectations.

Goldman Sachs was quick to respond to the result, highlighting that the company’s revenue and earnings per share missed by 5% and 9%, respectively.

It commented: “3Q22 revenue came in -5% below consensus (Visible Alpha Consensus Data), driven primarily by a -15% miss in ex-US devices (largely a reflection of persisting supply chain challenges, which were well flagged in advance but clearly still underestimated).”

“Gross margins declined (-150bps non-GAAP; -140bps GAAP) as widely anticipated freight and supply pressures continue to impact the business. These cost pressures were exacerbated by an increase in SG&A expenses above and beyond revenue growth, in contrast to prior quarters (SG&A increased +17% CC, above Group revenue of +14% CC).”

At present, Goldman Sachs has a buy rating and $35.80 price target on the ResMed share price. However, this could change in the coming days once it has fully absorbed this update.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Five healthcare workers standing together and smiling.
Healthcare Shares

Up 38% in a month, what’s sparking the recent Race Oncology share price run-up?

What a month it has been for Race Oncology shareholders.

Read more »

Three businesspeople leap high with the CBD in the background.
Healthcare Shares

Why is the Nanosonics share price jumping 10% on Wednesday?

Nanosonics shares are jumping on Wednesday...

Read more »

A happy male investor turns around on his chair to look at a friend while a laptop runs on his desk showing share price movements
Healthcare Shares

Why this broker is tipping the ResMed share price to rise 17%

A leading broker says ResMed shares can rise strongly from here...

Read more »

patient with doctor, medical company, medical insurance
Healthcare Shares

Beating the benchmark: Why this broker is betting on the CSL share price for outperformance

Could plasma demand boost the CSL share price?

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

Here’s what happened to the CSL share price in June

CSL shares were relatively positive performers in June...

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Up 13% in a month, Polynovo share price bounces back after being dumped from ASX 200

What's going on with the Polynovo share price?

Read more »

health workers shake hands and congratulate each other on good news
Share Gainers

This ASX All Ordindaries healthcare share is ripping 17% higher amid a new contract win

Investors seem to like the contract win from this healthcare player.

Read more »

Two researchers discussing results of a study with each other.
Healthcare Shares

Here’s how ASX 200 healthcare shares performed in June

Healthcare shares were a tad ill in June.

Read more »